Can a new PET tracer spot thyroid cancer recurrence more clearly?

NCT ID NCT07753499

Recruiting now Diagnosis Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial is evaluating whether a new PET/CT imaging tracer, 68Ga-MY6349, can detect recurrent or metastatic thyroid cancer more effectively than the standard 68Ga-FAPI tracer. Adults with a history of treated thyroid cancer who show signs of possible recurrence will receive both tracers and undergo imaging to compare their diagnostic accuracy. The goal is to see if the new tracer improves detection and helps guide clinical management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-MY6349, a radioactive tracer for PET/CT imaging
What this could lead to: If successful, this could provide a more accurate imaging method to detect recurrent or metastatic thyroid cancer, potentially guiding better treatment decisions.
What could go wrong: This is an early-stage diagnostic study, and the new tracer may not prove more accurate than existing methods. There are also risks associated with radiation exposure from PET/CT scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease neoplasm thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR THYROID CANCER TUMOR

Contacts and locations

Locations

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000
RECRUITING

Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.